Zoniporide hydrochloride

Research use only, not for human use.

Zoniporide hydrochloride is a selective inhibitor of NHE-1 with IC50 of 14 nM which is >150-fold selectivity versus other NHE isoforms. Zoniporide hydrochloride shows an IC50 of 59 nM for NHE-1-dependent swelling of human platelets.

Zoniporide hydrochloride is a selective inhibitor of NHE-1 with IC50 of 14 nM which is >150-fold selectivity versus other NHE isoforms. Zoniporide hydrochloride shows an IC50 of 59 nM for NHE-1-dependent swelling of human platelets.(In Vivo):In rats, Zoniporide hydrochloride (1 mg/kg; i.v.) shows the AUC0-∞ and t1/2 are 0.07 μg h/mL and 0.5 hours, respectively. In open chest anesthetized rabbits, Zoniporide hydrochloride (0.25, 1, 4 mg/kg; i.v.) dose-dependently reduces infarct size with an ED50 of 0.45 mg/kg/h. Zoniporide hydrochloride exhibits moderate plasma protein binding with t1/2 of 1.5h in monkeys.

——

Zoniporide (0.25-4 mg/kg; i.v.; every hour for 2 hours) elicits a dose-dependent reduction in infarct size (ED50=0.45 mg/kg/h) in open chest anesthetized rabbits.Zoniporide exhibits moderate plasma protein binding, has a t1/2 of 1.5 hours in monkeys, and has one major active metabolite.Zoniporide treatment shows the AUC0-∞ and t1/2 are 0.07 μg h/mL and 0.5 hours, respectively. Animal Model:Rabbit Dosage:0.25, 1, 4 mg/kg Administration:Every hour for 2 hours; intravenous injection Result:Elicited a significant dose-dependent reduction in infarct size in the anesthetized rabbit. The ED50 was 0.45 mg/kg/h.Animal Model:Rat Dosage:1 mg/kg Administration:Intravenous injection(Pharmacokinetic Analysis)Result:The AUC0-∞ and t1/2 were 0.07 μg h/mL and 0.5 hours, respectively.

CP-597396 hydrochloride

Membrane Transporter/Ion Channel

Sodium Channel

——

——

——

241800-97-5

356.81

C17H17ClN6O

>98% (HPLC)

——

Cl.O=C(NC(=N)N)C=1C=NN(C2=CC=CC3=NC=CC=C32)C1C4CC4

——

(-20℃)

With Ice Pack

≥ 2 years